Optimal Use of Targeted Agents for Advanced Gastrointestinal Stromal Tumours

Publisher： Karger

E-ISSN： 1423-0232|78|2|130-140

ISSN： 0030-2414

Source： Oncology, Vol.78, Iss.2, 2010-04, pp. : 130-140

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours

By  

Case Reports in Oncology, Vol. 4, Iss. 1, 2011-04 ,pp. : 204-210

Karger

Access to resources Recommend Favorite

Role of immune microenvironment in gastrointestinal stromal tumours

By  

HISTOPATHOLOGY, Vol. 72, Iss. 3, 2018-02 ,pp. : 405-413

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic characteristics of duodenal gastrointestinal stromal tumours

By  

BRITISH JOURNAL OF SURGERY, Vol. 102, Iss. 8, 2015-07 ,pp. : 959-964

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib

By  

CANCER, Vol. 121, Iss. 9, 2015-05 ,pp. : 1405-1413

John Wiley & Sons Inc

Access to resources Recommend Favorite

FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours

By Malle Philipp   Sorschag Manfred   Gallowitsch Hans-Jürgen  

Wiener Medizinische Wochenschrift, Vol. 162, Iss. 19-20, 2012-10 ,pp. : 423-429

Springer Publishing Company

Access to resources Recommend Favorite